Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | CDC25C | P30307 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095905 | 0.79 | HSD17B10 (0.40) | GSK3BALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL8234450 | 0.76 | HTR2A (0.37) | GSK3BALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL1096841 | 0.75 | MEN1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL18497872 | 0.73 | PBRM1 (0.38) | PBRM1TNKS2 | |
| SCHEMBL1708832 | 0.67 | TNKS2 (0.49) | GSK3BALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL31667419 | 0.67 | TNKS2 (0.49) | GSK3BALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL19573960 | 0.67 | TNKS2 (0.49) | GSK3BALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL19573959 | 0.67 | TNKS2 (0.49) | GSK3BALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29695366 | 0.67 | TNKS2 (0.49) | GSK3BALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL16385898 | 0.66 | LRRK2 (0.52) | GSK3BALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | disclosed |
| US-6956033-B2 | 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1306373-A1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, TRPV1 | GSK3B 1955/4885ALDH1A1 2167/4885KDM4E 1627/4885 |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | GSK3B 119/4885ALDH1A1 2636/4885KDM4E 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.